Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00123851
Recruitment Status : Completed
First Posted : July 26, 2005
Last Update Posted : April 28, 2009
OSI Pharmaceuticals
Hoffmann-La Roche
Genentech, Inc.
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by:
Dana-Farber Cancer Institute